phrykt

Syndax Pharmaceuticals Inc (SNDX): who owns it and who trades it

As of Nov 16, 2026, SNDX insiders reported 10 open-market sales worth $2.9M and no purchases in the last 12 months, with 4% of the sale value made under pre-set 10b5-1 plans. The largest seller was Michael A Metzger (CEO), with $1.4M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Syndax Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SNDX

243 funds and institutions reported SNDX shares worth $2.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.10.2%
Kynam Capital Management, LP9.1%
Goldman Sachs Group Inc6.6%
State Street Corp6.4%
Bank of America Corp4.6%
Vanguard Capital Management LLC4.4%
Deerfield Management Company, L.P.4.3%
Eversept Partners, LP3.2%
Geode Capital Management, LLC2.9%
Hood River Capital Management LLC2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.9.02M10.18%$197M+9%
Kynam Capital Management, LP8.05M9.09%$176MNo change
Goldman Sachs Group Inc5.86M6.61%$128M+17%
State Street Corp5.66M6.39%$124M+28%
Bank of America Corp4.05M4.57%$88.4M-5%
Vanguard Capital Management LLC3.93M4.43%$85.9M+3%
Deerfield Management Company, L.P.3.78M4.27%$82.6MNo change
Eversept Partners, LP2.80M3.16%$61.2M-3%
Geode Capital Management, LLC2.58M2.92%$56.5M+20%
Hood River Capital Management LLC2.56M2.89%$56.1M+9%
Kingdon Capital Management, L.l.c.2.50M2.82%$54.6MNo change
Franklin Resources Inc2.29M2.58%$50M+6%
Millennium Management LLC2.05M2.32%$44.9M+929%
California State Teachers Retirement System2.04M2.31%$93.5M+1884%
Vanguard Portfolio Management LLC1.92M2.17%$42M+11%
UBS Group AG1.89M2.14%$41.4M+64%
Elmind Capital, LP1.85M2.09%$40.6MNo change
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1.79M2.02%$39.1M+3%
Candriam S.C.A.1.70M1.91%$37M+83%
Soleus Capital Management, L.P.1.63M1.84%$35.6M-6%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SNDX insiders reported $0 of open-market purchases and $2.9M of sales. 4% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.9M
10 trades, 4 people
Sales under a 10b5-1 plan
4%
Share of sale value
Latest trade
Oct 29, 2026
Filed Oct 30, 2026

Purchases and sales by month

$1.3M$1.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 29, 2026Dennis PodlesakDirectorSale plan8,000$14.21$114KForm 4
Jul 8, 2026Michael A MetzgerCEOSale32,375$24.24$785KForm 4
Jun 12, 2026Nicholas A.J. BotwoodHead of R&DSale31,235$18.14$567KForm 4
Jun 11, 2026Nicholas A.J. BotwoodHead of R&DSale34,280$18.00$617KForm 4
Jun 1, 2026Keith A. GoldanCFOSale1,177$18.99$22.4KForm 4
Jun 1, 2026Michael A MetzgerCEOSale6,847$18.99$130KForm 4
Feb 9, 2026Michael A MetzgerCEOSale17,159$21.03$361KForm 4
Feb 9, 2026Keith A. GoldanCFOSale3,410$21.03$71.7KForm 4
Feb 6, 2026Michael A MetzgerCEOSale7,412$20.62$153KForm 4
Feb 6, 2026Keith A. GoldanCFOSale2,082$20.62$42.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Michael A MetzgerChief Executive Officer, Director–$1.4MJul 8, 2026
Nicholas A.J. BotwoodHead of R&D, CMO–$1.2MJun 12, 2026
Keith A. GoldanChief Financial Officer–$137KJun 1, 2026
Dennis PodlesakDirector–$114KOct 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SNDX short interest

Very high short interest. 21.2% of SNDX shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went down 13%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 18.92M SNDX shares were sold short, 21.2% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 2.95M shares, buying them all back would take about 6.4 trading days (days to cover).

Shares short, % of all shares

21.2%May 15Oct 3026.7%

Days to cover

6.4May 15Oct 3021.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202618.92M21.19%+5%2.95M6.4
Oct 15, 202618.00M20.16%-1%2.36M7.6
Sep 30, 202618.23M20.42%-12%2.15M8.5
Sep 15, 202620.66M23.14%-5%1.40M14.7
Aug 31, 202621.68M24.28%-5%1.10M19.6
Aug 14, 202622.90M25.65%+1%1.52M15.0
Jul 31, 202622.67M25.38%+9%1.22M18.6
Jul 15, 202620.82M23.49%-5%2.12M9.8
Jun 30, 202621.81M24.62%+10%2.55M8.6
Jun 15, 202619.86M22.41%+19%2.18M9.1
May 29, 202616.64M18.78%-23%1.04M16.0
May 15, 202621.71M24.50%+9%2.06M10.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Syndax Pharmaceuticals company events

Syndax Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. Jul 14, 2026AnnouncementSyndax Pharmaceuticals, Inc. issued a press release and presentation highlighting its late-stage programs and the next chapter of its R&D strategy, including new pipeline assets, during its R&D event held on July 14, 2026. Filing
  4. Jun 10, 2026AgreementEntry into a Material Agreement. Filing
  5. Jun 10, 2026LeadershipAt the Syndax Pharmaceuticals, Inc. 2026 Annual Meeting of Stockholders, the Company’s stockholders approved the Company’s 2026 Equity Incentive Plan, which the Board of Directors of the Company previously approved, subject to stockholder approval at the Annual Meeting. Filing
  6. Jun 4, 2026AgreementEntry into a Material Agreement. Filing
  7. Apr 30, 2026ResultsReleased financial results. Filing
  8. Feb 26, 2026ResultsReleased financial results. Filing
  9. Jan 12, 2026ResultsReleased financial results. Filing
  10. Dec 19, 2025RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Syndax Pharmaceuticals financials

Famous investors that hold SNDX

4 of the 50 well-known investors we track reported holding SNDX in their latest 13F filing. The largest position is Israel Englander's, worth $22.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.22M$22.9M0.0%-41%
Ken Griffin · Citadel AdvisorsQ3 2026204,510$3.8M0.0%-21%
Jim Simons · Renaissance TechnologiesQ3 2026192,071$3.6M0.0%-40%
Paul Tudor Jones · Tudor Investment CorpQ3 202642,986$808K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SNDX in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G5.2%
Nov 10, 2026STATE STREET CORPORATION13G5.2%

Questions about Syndax Pharmaceuticals Inc (SNDX) stock

Who owns the most SNDX stock?

The largest reported owner of Syndax Pharmaceuticals Inc (SNDX) is BlackRock, Inc., with 10.2% of the company. In total, 243 funds and institutions reported holding SNDX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are SNDX insiders buying or selling?

In the last 12 months, SNDX insiders reported no open-market purchases and 10 sales worth $2.9M. The latest trade was on Oct 29, 2026. See every trade.

What is the short interest in SNDX?

As of Oct 30, 2026, 18.92M SNDX shares were sold short, 21.2% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 2.95M shares, buying them all back would take about 6.4 trading days (days to cover). See the history.

Which famous investors hold SNDX?

4 of the 50 well-known investors we track reported SNDX in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $22.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.